Biotech Values

[BTH]

There are people on this board a lot smarter that you or I who were long ARQL. So was Ohad Hammer

It's called gamling. Like what most of biotech investing is; until you have an almost sure thing, like Ponatinib. Otherwise, it's trying to find some sort of solace in identifying risk/reward. I do have position in ARQL - because it still has HCC and other drugs behind, as well as cash - however, my size was small here, because the chart smelled outright bad news, and for reasons discussed here many times about the trial design. $300M looked cheap yesterday, looks even cheaper today. But its eons away from ever getting back to a $500M market cap.